12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Cleveland BioLabs preclinical data

Cleveland BioLabs reported data from 179 non-human primates in a blinded, placebo-controlled, dose-ranging study showing that a single injection of CBLB502 given 25 hours after a 70% lethal dose of total body irradiation met the primary endpoint by demonstrating a significant dose-response relationship on overall survival (OS) at day 60 (p=0.0021 for the trend up to 10 µg/kg...

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >